DBV Technologies S.A. Announces Proposed Global Offering - Seite 2

The offering of ADS will be made only by the means of a prospectus. When available, copies of the prospectus relating to the offering of ADS may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: [phone]; email: [e-mail]; Leerink Partners LLC,  Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telephone: [phone] ext. 6142; email: [e-mail]; and Bryan, Garnier & Co., Attention: Prospectus Department, 26 Avenue des Champs-Élysées, 75008 Paris France, telephone: [phone]; email: [e-mail].

A registration statement relating to the ADS has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. The ADS may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the ADS in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Copies of the Reference Document registered by the AMF on April 16th, 2014 under No. 14-017 and its update filed with the AMF on September 22nd, 2014 under No. D.14-0286-A01 are available free of charge at DBV Technologies' head office in Green Square, 80/84 rue des Meuniers - 92220 Bagneux - France, and on the website of the AMF (www.amf-france.org). A securities note (note d'opération) related to the admission to trading of the new shares on Euronext Paris will be submitted for visa to the AMF and will be published on the website of the AMF (www.amf-france.org).

About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure.